LoQus23 Therapeutics
Business Services · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Building 522 Babraham Research Campus, C...Website
www.loqus23.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About LoQus23 Therapeutics
LoQus23 is a biotech company based in Cambridge, UK, developing small molecule somatic expansion inhibitors for the treatment of Huntington's Disease and other triplet repeat disordersExplore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is LoQus23 Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if LoQus23 Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once LoQus23 Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
LoQus23 Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at LoQus23 Therapeutics
Product Launch: Get notified when LoQus23 Therapeutics launches new products
Check out if LoQus23 Therapeutics is spiking on competitors!
Click to see if LoQus23 Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on LoQus23 Therapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at LoQus23 Therapeutics
Find more new buyers
Compare Similar Companies to LoQus23 Therapeutics
Compare insights from companies similar to LoQus23 Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
LoQus23 Therapeutics
<$5M
1-10
Private
$46.4M
2019
N/A
Company Profile Activity
Activity Insights
LoQus23 Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
LoQus23 Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about LoQus23 Therapeutics.
LoQus23 Therapeutics financials insights
Gather financial insights about LoQus23 Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$46.4M
LoQus23 Therapeutics Tech Stack
A closer look at the technologies used by LoQus23 Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
Funding
Funding
Funding
LoQus23 Therapeutics News & Media
LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors
Dr Mozayeni brings deep experience in biotech corporate strategy and business development Appointment follows successful £35 million Series A fundraise at the end of 2024 to take its MSH3 inhibitors to treat Huntington's disease into the clinic CAMBRIDGE, England, Feb. 18, 2025...LoQus23 Therapeutics' Series A £35m will prioritise targets for Huntingdon's Disease
Funds for pre-clinical development and initial clinical studies of lead small molecule drug.In other news this week: Zepz bags €243M, Oriole Networks raises €20M ... - Silicon Canals
We have gathered all the news in this roundup that we missed to make sure that you stay updated in the ocean of tech innovations.LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington's disease
Financing led by leading life sciences venture capital firm Forbion, with participation from existing investors SV Health Investors' Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF) Lead programme targeting MutSβ set to enter the clinic in 2026, offering a potentially...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding LoQus23 Therapeutics
Sign Up For FreeTo access detailed company insights
LoQus23 is a biotech company based in Cambridge, UK, developing small molecule somatic expansion inhibitors for the treatment of Huntington's Disease and other triplet repeat disorders... Read More
